Radiopharm Theranostics Partners with GenesisCare
Tuesday, March 28, 2023
Radiopharm Theranostics and GenesisCare have announced a new two-year strategic research collaboration to develop novel radiopharmaceuticals for some complex, hard-to-treat cancers. Through the partnership, Radiopharm Theranostics and GenesisCare will conduct Phase 1 clinical trials in Australia to study the safety and tolerability of novel radiopharmaceuticals, focusing on areas of high unmet need in oncology.
As part of the collaboration, GenesisCare’s Contract Research Organisation (CRO) and Imaging Research Organisation (IRO), will implement three Phase 1 clinical trials in Australia, involving Radiopharm’s platform of radiopharmaceutical nanobodies.
The three Phase 1 clinical trials to be conducted by GenesisCare for Radiopharm under the research partnership are:
1. Phase 1 trial involving Radiopharm’s proprietary nanobody from its Nano-mAbs platform which targets the PDL1 expression in non-small cell lung cancer
2. Phase 1 trial involving Radiopharm’s PTPu targeting peptide in Brain Tumours
3. Phase 1 trial involving Radiopharm’s PSA targeting antibody which targets free human prostate kallikrein (PSA) in prostate cancer cells.
This R&D collaboration brings together two Australian healthcare companies interested in researching and developing new treatments in Australia.
